

## Publications CIC-1427 en 2021

Auteurs	Titre	Journal	N° WOS/PubMed
<b>Zineb Ghrieb</b> , <b>Souhil Allaoua</b> , <b>Jin Huanga</b> , <b>Nathalie Langner</b> , <b>Florène François</b> , <b>Corinne Maréchal</b> , <b>Majdi Jebali</b> , <b>Céleste Lebbé</b> , <b>Abdenmour Chellah</b> , <b>Anne Bergeron</b> , <b>Jean-Jacques Kiladjian</b> , <b>Rafael Daltro De Oliveira</b> , <b>Juliette Soret-Dulphy</b> , <b>Lina Benajiba</b>	Un exemple de réorganisation dans le fonctionnement d'un Centre d'investigations cliniques en période de confinement national suite à la pandémie COVID-19	Thérapie	<a href="https://doi.org/10.1016/j.therap.2021.02.003">https://doi.org/10.1016/j.therap.2021.02.003</a>
Eytan M Stein , Daniel J DeAngelo , Jörg Chromik , Manik Chatterjee , Sebastian Bauer , Chia-Chi Lin , Cristina Suarez , Filip De Vos , Neeltje Steeghs , Phillippe A Cassier , David Tai , <b>Jean-Jacques Kiladjian</b> , Noboru Yamamoto , Rogier Mous , Jordi Esteve , Hironobu Minami , Stéphane Ferretti , Nelson Guerreiro , Christophe Meille , Rajkumar Radhakrishnan , Bernard Pereira , Luisa Mariconti , Ensar Halilovic , Claire Fabre , Cecilia Carpio	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia	Clinical Cancer Research	<a href="https://doi.org/10.1158/1078-0432.CCR-21-1295">DOI: 10.1158/1078-0432.CCR-21-1295</a>
<b>Jean-Jacques Kiladjian</b> , Fabien Despas	Hemato-oncopharmacology: Drugs and cancer	Thérapie	<a href="https://doi.org/10.1016/j.therap.2021.12.004">DOI: 10.1016/j.therap.2021.12.004</a>
Dikelele Elessa , <b>Lin-Pierre Zhao</b> , <b>Rafael Daltro De Oliveira</b> , Nabih Maslah, <b>Juliette Soret-Dulphy</b> , Emmanuelle Verger , <b>Clemence Marcault</b> , Nathalie Parquet , <b>Pierre Fenaux</b> , <b>Lionel Ades</b> , <b>Emmanuel Raffoux</b> , Stephane Giraudier, Olivier Fain, Bruno Cassinat, <b>Jean-Jacques Kiladjian</b> , Arsene Mekinian, <b>Lina Benajiba</b>	Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID)	Blood	<a href="https://doi.org/10.1182/blood-2021-152302">https://doi.org/10.1182/blood-2021-152302</a>
Srdan Verstovsek, Andrew T. Kuykendall, Ronald Hoffman, Yelena Ginzburg, Naveen Pemmaraju, Frank Valone, Nishit B Modi, Sarita Khanna, Paula G. O'Connor, Suneel K Gupta, <b>Jean-Jacques Kiladjian</b>	A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera	Blood	<a href="https://doi.org/10.1182/blood-2021-149219">https://doi.org/10.1182/blood-2021-149219</a>
Jeanne M. Palmer, Ruben A. Mesa, Stephen T. Oh, Raajit Rampal, Sarah A Buckley, Karisse Roman-Torres, Srdan Verstovsek, John Mascarenhas, Alessandro M. Vannucchi, <b>Jean-Jacques Kiladjian</b> , Claire N. Harrison, Prithviraj Bose, Adam R Craig, Aaron T. Gerds	The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study	Blood	<a href="https://doi.org/10.1182/blood-2021-144505">https://doi.org/10.1182/blood-2021-144505</a>

Auteurs	Titre	Journal	N° WOS/PubMed
<b>Jean-Jacques Kiladjian</b> , Kohei Shitara, Lee Stephen Rosen, Sun Young Rha, Aiwu He, Do-Youn Oh, Davide Melisi, Satoru Iwasa, Yixing Jiang, Sherry Liu, Osamu Takahashi, Vincent Ribrag	A Phase 2 Study of Futibatinib (TAS-120) in Patients with Myeloid or Lymphoid Neoplasms Harboring Fibroblast Growth Factor Receptor (FGFR) 1 Rearrangements	Blood	<a href="https://doi.org/10.1182/blood-2021-150630">https://doi.org/10.1182/blood-2021-150630</a>
<b>Lin-Pierre Zhao</b> , <b>Marine Cazaux</b> , Nabih Maslah, <b>Rafael Daltro De Oliveira</b> , Emmanuelle Verger, <b>Juliette Soret-Dulphy</b> , <b>Clemence Marcault</b> , Nathalie Parquet, Christine Dosquet, William Vainchenker, <b>Emmanuel Raffoux</b> , <b>Stephane Giraudier</b> , <b>Jean-Jacques Kiladjian</b> , Bruno Cassinat, <b>Lina Benajiba</b>	Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis	Blood	<a href="https://doi.org/10.1182/blood-2021-149473">https://doi.org/10.1182/blood-2021-149473</a>
Tiziano Barbui, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Greta Carioli, Marta Sobas, Elena Maria Elli, Elisa Rumi, Valerio De Stefano, Francesca Lunghi, Monia Marchetti, Rosa Daffini, Mercedes Gasior Kabat, Beatriz Cuevas, Laura Maria Fox, Marcio Andrade, Francesca Palandri, Paola Guglielmelli, Giulia Benevolo, Claire N. Harrison, Maria Angeles Foncillas, Massimiliano Bonifacio, Alberto Alvarez-Larran, <b>Jean-Jacques Kiladjian</b> , Estefanía Bolaños, Andrea Patriarca, Keina Quiroz, Martin Griesshammer, Valentín Garcia Gutierrez, Alberto Marin Sanchez, Elena Magro, Marco Ruggeri, Juan Carlos Hernandez Boluda, Santiago Osorio, Gonzalo Carreño Gomez-Tarragona, Miguel Sagüés, Rajko Kusec, Begoña Navas, Anna Angona, Blanca Xicoy, Emma Lopez Abadia, Steffen Koschmieder, Daniele Cattaneo, Cristina Bucelli, Edyta Cichocka, Anna Masternak, Fabrizio Cavalca, Oscar Borsani, Silvia Betti, Marta Bellini, Natalia Curto-Garcia, Alessandro Rambaldi, Alessandro Vannucchi	Second Versus First Wave of COVID-19 in Patients with MPN	Blood	<a href="https://doi.org/10.1182/blood-2021-146134">https://doi.org/10.1182/blood-2021-146134</a>
John Mascarenhas, Claire N. Harrison, <b>Jean-Jacques Kiladjian</b> , Rami S. Komrokji, Steffen Koschmieder, Alessandro Vannucchi, Tymara Berry, Laurie Sherman, Souria Dougherty, Libo Sun, Fei Huang, Ying Wan, Faye Feller, Aleksandra Rizo, Srdan Verstovsek	A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi)	Blood	<a href="https://doi.org/10.1182/blood-2021-148931">https://doi.org/10.1182/blood-2021-148931</a>

Auteurs	Titre	Journal	N° WOS/PubMed
Eytan M. Stein, Jörg Chromik, Cecilia Carpio, Rogier Mous, <b>Jean-Jacques Kiladjian</b> , Gheath Alatrash, Antonio Curti, Charles Craddock, Christoph Schmid, Robert Zeiser, Lamis K. Eldjerou, Hans-Jochen Jochen Weber, Claire Fabre, Jeffrey Scott, Daniel J. DeAngelo	Siremadlin (HDM201) Is Well Tolerated and Demonstrates Clinical Activity in Patients with Acute Myeloid Leukemia Who Have Relapsed after Allogeneic Stem Cell Transplantation: A Subst	Blood	<a href="https://doi.org/10.1182/blood-2021-149751">https://doi.org/10.1182/blood-2021-149751</a>
<b>Jean-Jacques Kiladjian</b> , Ayalew Tefferi, Francesco Passamonti, Alessandro Vannucchi, Moshe Talpaz, Francisco Cervantes, Claire N. Harrison, Ruben A. Mesa, John Mascarenhas, Nicolaas Schaap, Srdan Verstovsek, Timothy Devos, Shelonitda Rose, Jun Zhang, Oumar Sy, Animesh Pardanani	Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly	Blood	<a href="https://doi.org/10.1182/blood-2021-147618">https://doi.org/10.1182/blood-2021-147618</a>
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, <b>Jean-Jacques Kiladjian</b>	Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials	Blood	<a href="https://doi.org/10.1182/blood-2021-152328">https://doi.org/10.1182/blood-2021-152328</a>
Pankit Vachani, Andrzej Lange, Regina Garcia Delgado, Haifa Kathrin Al-Ali, Jesus Maria Hernández-Rivas, <b>Jean-Jacques Kiladjian</b> , Alessandro Vannucchi, Andrew Charles Perkins, Venu Valmeekam, Cecile Marie Krejsa, Anne Uyei, Jesse McGreivy, Wayne P. Rothbaum, John Mascarenhas, Srdan Verstovsek	Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)	Blood	<a href="https://doi.org/10.1182/blood-2021-147543">https://doi.org/10.1182/blood-2021-147543</a>
Srdan Verstovsek, <b>Jean-Jacques Kiladjian</b> , Alessandro M. Vannucchi, Ruben A. Mesa, Robyn Scherber, J.E. Hamer-Maansson, Claire N. Harrison	Does Early Intervention in Myelofibrosis Impact Outcomes? a Pooled Analysis of the Comfort I and II Studies	Blood	<a href="https://doi.org/10.1182/blood-2021-150894">https://doi.org/10.1182/blood-2021-150894</a>
Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben A. Mesa, Claire N. Harrison, Giovanni Barosi, <b>Jean-Jacques Kiladjian</b> , H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Vishwanath Gharpure, Christopher Hernandez, Tianhua Wang, Moshe Talpaz	Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial	Blood	<a href="https://doi.org/10.1182/blood-2021-147607">https://doi.org/10.1182/blood-2021-147607</a>

Auteurs	Titre	Journal	N° WOS/PubMed
Jason Gotlib, <b>Jean-Jacques Kiladjian</b> , Alessandro Vannucchi, Alessandro Rambaldi, Andreas Reiter, William Shomali, Tracy I. George, Jay L. Patel, Philomena Colucci, Chris Walker, Huiling Zhen, Srdan Verstovsek	A Phase 2 Study of Pemigatinib (FIGHT-203; INCB054828) in Patients with Myeloid/Lymphoid Neoplasms (MLNs) with Fibroblast Growth Factor Receptor 1 (FGFR1) Rearrangement (MLN FGFR1 )	Blood	<a href="https://doi.org/10.1182/blood-2021-148103">https://doi.org/10.1182/blood-2021-148103</a>
Claire N. Harrison, Abdurraheem Yacoub, Bart L. Scott, Adam J. Mead, Aaron T. Gerds, <b>Jean-Jacques Kiladjian</b> , Ruben A. Mesa, Miklos Egyed, Christof Scheid, Valentín Garcia Gutierrez, Sarah A Buckley, Kris Kanellopoulos, John Mascarenhas	Long-Term Treatment with Pacritinib on a Compassionate Use Basis in Patients with Advanced Myelofibrosis	Blood	<a href="https://doi.org/10.1182/blood-2021-148793">https://doi.org/10.1182/blood-2021-148793</a>
John Mascarenhas, Prithviraj Bose, <b>Jean-Jacques Kiladjian</b> , Ruben A. Mesa, Aaron T. Gerds, Vikas Gupta, Claire N. Harrison, Abdurraheem Yacoub, Valentín Garcia Gutierrez, Alessandro M. Vannucchi, Christof Scheid, Patricia Velez Tenza, Sarah A Buckley, Karisse Roman-Torres, Stephen T. Oh, Marta Sobas, David Lavie, Srdan Verstovsek	A Retrospective Head-to-Head Comparison between Pacritinib and Ruxolitinib in Patients with Myelofibrosis and Moderate to Severe Thrombocytopenia	Blood	<a href="https://doi.org/10.1182/blood-2021-146675">https://doi.org/10.1182/blood-2021-146675</a>
Pankit Vachani, Andrzej Lange, Regina Garcia Delgado, Haifa Kathrin Al-Ali, Jesus Maria Hernández-Rivas, <b>Jean-Jacques Kiladjian</b> , Alessandro Vannucchi, Andrew Charles Perkins, Venu Valmeekam, Cecile Marie Krejsa, Anne Uyei, Jesse McCreivy, Wayne P. Rothbaum, John Mascarenhas, Srdan Verstovsek	Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)	Blood	<a href="https://doi.org/10.1182/blood-2021-147543">https://doi.org/10.1182/blood-2021-147543</a>
<b>Lin-Pierre Zhao</b> , Nabih Maslah, <b>Rafael Daltro De Oliveira</b> , Emmanuelle Verger, <b>Juliette Soret-Dulphy</b> , <b>Clemence Marcault</b> , Nathalie Parquet, Christine Dosquet, William Vainchenker, <b>Emmanuel Raffoux</b> , <b>Stephane Giraudier</b> , <b>Jean-Jacques Kiladjian</b> , Bruno Cassinat, <b>Lina Benajiba</b> , <b>Marine Cazaux</b>	Chronic Exposure to Cytoreductive Treatment Shapes Clonal Evolution in Myeloproliferative Neoplasms	Blood	<a href="https://doi.org/10.1182/blood-2021-152622">https://doi.org/10.1182/blood-2021-152622</a>
<b>Lina Benajiba</b> , <b>Jean-Jacques Kiladjian</b>	The challenge of targets and drug discovery using large-scale screening approaches in onco-hematology	Thérapie	<a href="https://doi.org/10.1016/j.therap.2021.11.007">https://doi.org/10.1016/j.therap.2021.11.007</a>
Andrew T. Kuykendall <sup>1</sup> · Libo Sun <sup>2</sup> · John Mascarenhas <sup>3</sup> · <b>Jean-Jacques Kiladjian</b> <sup>4</sup> · Alessandro M. Vannucchi <sup>5</sup> · Julia Wang <sup>6</sup> · Qi Xia <sup>6</sup> · Eugene Zhu <sup>6</sup> · Faye Feller <sup>2</sup> · Aleksandra Rizo <sup>2</sup> · Jacqueline Bussolari <sup>6</sup> · Ying Wan <sup>2</sup> · Rami Komrokji <sup>1</sup>	Favorable overall survival with imetelstat in relapsed/refractory myelofibrosis patients compared with real-world data	Annals of Hematology	<a href="https://doi.org/10.1007/s00277-021-04683-w">https://doi.org/10.1007/s00277-021-04683-w</a>

Auteurs	Titre	Journal	N° WOS/PubMed
Srdan Verstovsek 1 , Ruben Mesa 2 , Moshe Talpaz 3 , <b>Jean-Jacques Kiladjian</b> 4 , Claire N Harrison 5 , Stephen T Oh 6 , Alessandro M Vannucchi 7 , Raajit Rampal 8 , Bart L Scott 9 , Sarah A Buckley 10 , Adam R Craig 10 , Karisse Roman-Torres 10 , John O Mascarenhas 11	Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia	Haematologica	<a href="https://doi.org/10.3324/haematol.2021.279415">https://doi.org/10.3324/haematol.2021.279415</a>
Alberto Alvarez-Larrán, Emanuela Sant'Antonio, Claire Harrison, <b>Jean-Jacques Kiladjian</b> , Martin Griesshammer, Ruben Mesa, et al,	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet	The Lancet Haematology	<a href="https://doi.org/10.1016/S2352-3026(21)00204-0">https://doi.org/10.1016/S2352-3026(21)00204-0</a>
John Mascarenhas , Aaron Gerds, <b>Jean-Jacques Kiladjian</b> , Konstanze Döhner, Sarah Buckley, Jennifer Smith, Adam Craig, Simran Singh, Srdan Verstovsek, Claire Harrison	Pacifica: A Randomized, Controlled Phase 3 Study of Pacritinib Vs. Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocytopenia Myelofibrosis with Severe Thrombocytopenia (Platelet Count <50,000/mL)	American Society of Hematology	<a href="https://doi.org/10.1182/blood-2019-129245">https://doi.org/10.1182/blood-2019-129245</a>
<b>Jean-Jacques Kiladjian 1*</b> , Uwe Platzbecker 2, Jiří Mayer 3, Árpád Illés 4, Witold Prejzner 5, Tomasz Woźny 6, Nikolay Tzvetkov 7, Alessandro M Vannucchi 8, Ilya Kirgner 9, Zsolt Nagy 10, Sebastian Grosicki 11, Åsa Derolf 12, Mihaela Cornelia Lazaroiu 13, Sung-Soo Yoon 14, Yeow Tee Goh 15, Nikolas von Bubnoff 16, Ruben Mesa 17, Barbara J Klencke 18, Rafe Donahue 18, Srdan Verstovsek 19	Poster: MPN-106: Improved Transfusion Independence Rates for Momelotinib vs Ruxolitinib in Anemic JAKi-Naïve Myelofibrosis Patients are Independent of Baseline Platelet or Transfusion Stat	American Society of Hematology	<a href="https://doi.org/10.1016/S2152-2650(21)01453-1">https://doi.org/10.1016/S2152-2650(21)01453-1</a>
Claire Harrison 1*, <b>Jean-Jacques Kiladjian</b> 2, Srdan Verstovsek 3, Alessandro Vannucchi 4, Ruben Mesa 5, Andreas Reiter 6, Jun Zhang 7, Shelonitda Rose 7, John Mascarenhas 8 1Guy's and St Thomas'	Poster: MPN-164 Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials	American Society of Hematology	<a href="http://dx.doi.org/10.1016/S2152-2650(21)01454-3">http://dx.doi.org/10.1016/S2152-2650(21)01454-3</a>

Ruben Mesa 1*, Stacie Hudgens 2, Lysbeth Floden 2, Jeanne Palmer 3, Vikas Gupta 4, Donal McLornan 5, Mary Frances McMullin 6, <b>Jean-Jacques Kiladjian</b> 7, Lynda Foltz 8, Uwe Platzbecker 9, Maria Laura Fox 10, Adam Mead 11, David Ross 12, Stephen Oh 13, Andrew Perkins 14, Michael Leahy 15, Samineh Deheshi 16, Rafe Donahue 16, Barbara Klencke 16, Srdan Verstovsek 17	Poster: MPN-303 Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients	American Society of Hematology	<a href="https://doi.org/10.1200/JCO.2021.39.15_SUPPL.E19040">https://doi.org/10.1200/JCO.2021.39.15_SUPPL.E19040</a>
Ruben Mesa 1*, Stephen T Oh 2, Aaron T Gerds 3, Vikas Gupta 4, John Catalano 5, Francisco Cervantes 6, Timothy Devos 7, <b>Jean-Jacques Kiladjian</b> 8, Ewa Lech-Maranda 9, Donal McLornan 10, Jeanne Palmer 11, Uwe Platzbecker 12, Jacek Treliński 13, Kazuya Shimoda 14, Rafe Donahue 15, Bryan Strouse 15, Mark Kowalski 15,	Poster: MPN-356 Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib	American Society of Hematology	<a href="https://doi.org/10.1016/S2152-2650(21)01836-X">https://doi.org/10.1016/S2152-2650(21)01836-X</a>
Nabih Maslah, Odonchimeg Ravdan, Louis Drevon, Emmanuelle Verger, Célia Belkhodja, Christine Chomienne, Bruno Cassinat, <b>Jean-Jacques Kiladjian</b> , Stéphane Giraudier, Marie-Hélène Schlageter	Revisiting Diagnostic performances of serum erythropoietin level and JAK2 mutation for polycythemia: analysis of a cohort of 1090 patients with red cell mass measurement	British journal of hematology	<a href="https://doi.org/10.1111/bjh.17848">https://doi.org/10.1111/bjh.17848</a>
Matthieu Mosca, Gurvan Hermange, Amandine Tisserand, Robert Noble, Christophe Marzac, Caroline Marty, Cécile Le Sueur, Hugo Campario, Gaëlle Vertenoil, Mira El-Khoury, Cyril Catelain, Philippe Rameau, Cyril Gella, Julien Lenglet, Nicole Casadevall, Rémi Favier, Eric Solary, Bruno Cassinat, <b>Jean-Jacques Kiladjian</b> , Stefan N. Constantinescu, Florence Pasquier, Michael E. Hochberg, Hana Raslova, Jean-Luc Villeval, François Girodon, William Vainchenker, Paul-Henry Cournaud, Isabelle Plo	Inferring the dynamic of mutated hematopoietic stem and progenitor cells induced by IFN $\alpha$ in myeloproliferative neoplasms	Blood	<a href="https://doi.org/10.1182/blood.2021010986">https://doi.org/10.1182/blood.2021010986</a>
<b>Marie Robin</b> , Raphael Porcher, Corentin Orvain, Jacques-Olivier Bay, Fiorenza Barraco, Anne Huynh, Amandine Charbonnier, Edouard Forcade, Sylvain Chantepie, Claude Bulabois, Ibrahim Yakoub-Agha, Marie Detrait, <b>David Michonneau</b> , Pascal Turlure, Nicole Raus, Françoise Boyer, Felipe Suarez, Laure Vincent, Stéphanie N. Guyen, Jérôme Cornillon, Alban Villate, Brigitte Dupriez, Bruno Cassinat, Valérie Rolland, Marie Hélène Schlageter, <b>Gérard Socié</b> & <b>Jean-Jacques Kiladjian</b>	Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups	Bone Marrow Transplant	<a href="https://doi.org/10.1038/s41409-021-01252-7">https://doi.org/10.1038/s41409-021-01252-7</a>

Léa Sureau, Corentin Orvain, Jean-Christophe Ianotto, Valérie Ugo, <b>Jean-Jacques Kiladjian</b> , Damien Luque Paz & Jérémie Riou	Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis	Blood Cancer Journal	<a href="https://doi.org/10.1038/s41408-021-00526-z">https://doi.org/10.1038/s41408-021-00526-z</a>
Stephen T. Oh, <b>Jean-Jacques Kiladjian</b> , Francesca Palandri, Jason R. Gotlib, Sanjay Mohan, Haris Ali, Ekatherine Asatiani, Francis Seguy, Feng Zhou and Srđan Verstovsek	Abstract CT216: A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)	American Association for Cancer Research	<a href="https://doi.org/10.1158/1538-7445.AM2021-CT216">https://doi.org/10.1158/1538-7445.AM2021-CT216</a>
John Mascarenhas, MD1; Rami S. Komrokji, MD2; Francesca Palandri, MD3; Bruno Martino, MD4; Dietger Niederwieser, MD, PhD5; Andreas Reiter, MD6; Bart L. Scott, MD7; Maria R. Baer, MD8; Ronald Hoffman, MD1; Olatoyosi Odenike, MD9; Alessandro M. Vannucchi, MD10; Jacqueline Bussolari, PhD11; Eugene Zhu, PhD11; Esther Rose, MD11; Laurie Sherman, BSN12; Souria Dougherty, BS, MBA12; Libo Sun, PhD12; Fei Huang, PhD12; Ying Wan, PhD12; Faye M. Feller, MD12; Aleksandra Rizo, MD, PhD12; and <b>Jean-Jacques Kiladjian, MD, PhD13</b>	Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis	Journal of Clinical Oncology	<a href="https://doi.org/10.1200/JCO.20.02864">https://doi.org/10.1200/JCO.20.02864</a>
R.Mesa1S.Hudgens2L.Floden2J.Palmer3V.Gupta4D.P.McLornan5M.F.McMullin6 <b>J.J. Kiladjian</b> 7L.Foltz8U.Platzbecker9M.L.Fox10A.J.Mead11D.M.Ross12S.T.Oh13A.Perkins14M.F.Leahy15S.Deheshi16R.Donahue17B.J.Klencke17S.Verstovsek18	PCN19 Beyond a Binary Endpoint: Longitudinal and Individual Symptom Analyses from the Simplify-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor Naive Myelofibrosis Patients	Science Direct	<a href="https://doi.org/10.1016/j.jval.2021.04.111">https://doi.org/10.1016/j.jval.2021.04.111</a>
<b>Jean-Jacques Kiladjian</b> , Uwe Platzbecker, Jiří Mayer, Árpád Illés, Witold Prejzner, Tomasz Woźny, Nikolay Tzvetkov, Alessandro M. Vannucchi, Ilya Kirgner, Zsolt Nagy, Sebastian Grosicki, Åsa Derolf, Mihaela Cornelia Lazaroiu, Sung-Soo Yoon, Yeow Tee Goh, Nikolas von Bubnoff, Srđan Verstovsek, Barbara J. Klencke, Rafe Donahue, Ruben A. Mesa	Improved transfusion independence rates for momelotinib versus ruxolitinib in anemic JAKi naïve myelofibrosis patients independent of baseline platelet or transfusion status.	Journal of clinical oncology ASCO	<a href="https://doi.org/10.1200/JCO.2021.39.15_SUPPL.E19039">https://doi.org/10.1200/JCO.2021.39.15_SUPPL.E19039</a>
Srđan Verstovsek, Haifa Kathrin Al-Ali, John Mascarenhas, Adam J. Mead, Andrew Perkins, Alessandro M. Vannucchi, Anne Uyei, Wayne P. Rothbaum, Jesse McGreivy, <b>Jean-Jacques Kiladjian</b>	BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).	Journal of clinical oncology ASCO	<a href="https://doi.org/10.1200/JCO.2021.39.15_SUPPL.TPS7057">https://doi.org/10.1200/JCO.2021.39.15_SUPPL.TPS7057</a>

Ruben A. Mesa, Stephen T. Oh, Aaron Thomas Gerds, Vikas Gupta, John V. Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, <b>Jean-Jacques Kiladjian</b> , Ewa Lech-Maranda, Donal P. McLornan, Jeanne Palmer, Uwe Platzbecker, Jacek Trelinski, Kazuya Shimoda, Rafe Donahue, Bryan Strouse, Mark Marion Kowalski, Srdan Verstovsek	Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.	Journal of clinical oncology ASCO	<a href="https://doi.org/10.1200/JCO.2021.39.15_SUPPL.7046">https://doi.org/10.1200/JCO.2021.39.15_SUPPL.7046</a>
Clémence Marcault , Lin-Pierre Zhao , Nabih Maslah , Emmanuelle Verger , <b>Rafael Daltro de Oliveira</b> , <b>Juliette Soret-Dulphy</b> , Marine Cazaux , Nicolas Gauthier , Blandine Roux , Emmanuelle Clappier , Nathalie Parquet , Christine Dosquet , <b>Delphine Réa</b> , Jean-Marc Zini 6 , William Vainchenker 6 , Emmanuel Raffoux , Stéphane Giraudier , <b>Jean-Jacques Kiladjian</b> , Bruno Cassinat , <b>Lina Benajiba</b>	Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms (MPN)	Blood	<a href="https://doi.org/10.1182/blood.2020010402">https://doi.org/10.1182/blood.2020010402</a>
Claire N. Harrison,corresponding author1 Nicolaas Schaap,2 Alessandro M. Vannucchi,3 <b>Jean-Jacques Kiladjian</b> ,4 Eric Jourdan,5 Richard T. Silver,6 Harry C. Schouten,7 Francesco Passamonti,8 Sonja Zweegman,9 Moshe Talpaz,10 Srdan Verstovsek,11 Derek Tang,12 Pranav Abraham,12 Jennifer Lord-Bessen,12 Shelonitda Rose,12 Shien Guo,13 Weiqin Liao,13 and Ruben A. Mesa	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial	HemaSphere	<a href="https://dx.doi.org/10.1097%2FH9S.0000000000000562">https://dx.doi.org/10.1097%2FH9S.0000000000000562</a>
Ruben A Mesa, MD, Nicolaas Schaap, MD PhD, Alessandro M Vannucchi, MD, <b>Jean-Jacques Kiladjian, MD PhD</b> , Francesco Passamonti, MD, Sonja Zweegman, Moshe Talpaz, MD, Srdan Verstovsek, MD PhD, Shelonitda Rose, Derek Tang, PhD BSPHarm, Angela Hu, MS, EDM, Carrie Brownstein, MD, Shien Guo, PhD, Xiaomei Ye, MS, Claire N Harrison,	Health-Related Quality of Life (HRQoL) in Patients with Myelofibrosis Treated with Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in the Randomized, Placebo-Controlled, Phase III JAKARTA Study	Blood	<a href="https://doi.org/10.1182/blood-2019-129020">https://doi.org/10.1182/blood-2019-129020</a>
Juliette Lambert, Joseph Saliba,Carolina Calderon, Karine Sii-Felice,Mohammad Salma, Valérie Edmond,6 Jean-Claude Alvarez, Marc Delord, Caroline Marty, Isabelle Plo, <b>Jean-Jacques Kiladjian</b> ,Eric Soler, William Vainchenker, Jean-Luc Villeval, <b>Philippe Rousselot</b> , and Stéphane Prost	PPAR-γ agonists promote the resolution of myelofibrosis in preclinical models	The Journal of clinical investigation	<a href="http://dx.doi.org/10.1172/JCI136713">http://dx.doi.org/10.1172/JCI136713</a>



<p>Onima Chowdhury 1, Jennifer O'Sullivan 1, Nikolaos Barkas 1, Guanlin Wang 1, Gemma Buck 1, Angela Hamblin 1, Ayalew Tefferi 2, Haifa K Al-Ali 3, Giovanni Barosi 4, Timothy Devos 5, Heinz Gisslinger 6, Qian Jiang 7, <b>Jean-Jacques Kiladjian</b> 8, Ruben Mesa 9, Francesco Passamonti 10, Vincent Ribrag 11, Gary Schiller 12, Alessandro M Vannucchi 13, Daobin Zhou 14, Mary Frances McMullin 15, Jianhua Zhong 16, Robert Peter Gale 17, Adam J Mead</p>	<p>Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide</p>	<p>Leukemia</p>	<p><a href="https://www.nature.com/articles/s41375-020-0979-6">https://www.nature.com/articles/s41375-020-0979-6</a></p>
<p>Ralfs Buks, Mégane Brusson, Sylvie Cochet, Tatiana Galochkina, Bruno Cassinat, Ivan Nemazanyy, Thierry Peyrard, <b>Jean-Jacques Kiladjian</b>, Alexandre G de Brevin, Slim Azouzi, Wassim El Nemer</p>	<p>ABCG2 Is Overexpressed on Red Blood Cells in Ph-Negative Myeloproliferative Neoplasms and Potentiates Ruxolitinib-Induced Apoptosis</p>	<p>International journal of molecular sciences</p>	<p><a href="https://doi.org/10.3390/ijms22073530">https://doi.org/10.3390/ijms22073530</a></p>
<p>Aline Renneville, Jessica A Gasser, Daniel E Grinshpun, Pierre M Jean Beltran, Namrata D Udeshi, Mary E Matyskiela, Thomas Clayton, Marie McConkey, Kaushik Viswanathan, Alexander Tepper, Andrew A Guirguis, Rob S Sellar, Sophie Cotteret, Christophe Marzac, Véronique Saada, Stéphane De Botton, <b>Jean-Jacques Kiladjian</b>, Jean-Michel Cayuela, Mark Rolfe, Philip P Chamberlain, Steven A Carr, Benjamin L Ebert</p>	<p>Avadomide Induces Degradation of ZMYM2 Fusion Oncoproteins in Hematologic Malignancies</p>	<p>Blood Cancer Discovery</p>	<p><a href="https://doi.org/10.1158/2643-3230.bcd-20-0105">https://doi.org/10.1158/2643-3230.bcd-20-0105</a></p>
<p>Damien Luque Paz, Jérémie Riou, Emmanuelle Verger, Bruno Cassinat, Aurélie Chauveau, Jean-Christophe Iannotto, Brigitte Dupriez, Françoise Boyer, Maxime Renard, Olivier Mansier, Anne Murati, Jérôme Rey, Gabriel Etienne, Véronique Mansat-De Mas, Suzanne Tavitian, Olivier Nibourel, Stéphane Girault, Yannick Le Bris, François Girodon, Dana Ranta, Jean-Claude Chomel, Pascale Cony-Makhoul, Pierre Sujobert, Margot Robles, Raouf Ben Abdelali, Olivier Kosmider, Laurane Cottin, Lydia Roy, Ivan Sloma, Fabienne Vacheret, Mathieu Wemeau, Pascal Mossuz, Borhane Slama, Vincent Cussac, Guillaume Denis, Anouk Walter-Petrich, Barbara Burrioni, Nathalie Jézéquel, Stéphane Giraudier, Eric Lippert, Gérard Socié, <b>Jean-Jacques Kiladjian</b>, Valérie Ugo</p>	<p>Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: A FIM study</p>	<p>Blood advances</p>	<p><a href="https://doi.org/10.1182/bloodadvances.2020003444">https://doi.org/10.1182/bloodadvances.2020003444</a></p>

<p>Sylvie Tondeur , Franciane Paul , Jérémie Riou , Olivier Mansier , Dana Ranta , Lenaïg Le Clech , Eric Lippert , Suzanne Tavitian , Driss Chaoui , Mélanie Mercier , Benoit De Renzis , Laurane Cottin , Bruno Cassinat , Jean-Marie Chrétien , Jean-Christophe Ianotto , Olivier Allangba , Christophe Marzac , Laurent Voillat , Françoise Boyer , Corentin Orvain , Mathilde Hunault-Berger , François Girodon , <b>Jean-Jacques Kiladjian</b> , Valérie Ugo , Damien Luque Paz</p>	<p>Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study</p>	<p>Leukemia</p>	<p><a href="https://doi.org/10.1038/s41375-020-0991-x">https://doi.org/10.1038/s41375-020-0991-x</a></p>
<p>Jill Corre , Michele Sabbah , Fredrik Schjesvold , Amer M. Zeidan , Francesco Buccisano , David Sallman , Mario Mazzucato , Leigh A. Madden , Maurizio Martini , Eric Van Breda , Riccardo Dolcetti , Alessandro Busca , Gordon Cook , Francesco Onida , Annibale Versari , <b>Jean-Jacques Kiladjian</b> , Roland B. Walter , Laurent Garderet , Marie Robin and Alberto Signore</p>	<p>Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2</p>	<p>Hemato</p>	<p><a href="https://doi.org/10.3390/hemato2010004">https://doi.org/10.3390/hemato2010004</a></p>
<p>Srdan Verstovsek , Chih-Cheng Chen , Miklós Egyed , Martin Ellis , Laura Fox , Yeow T Goh , Vikas Gupta , Claire Harrison , <b>Jean-Jacques Kiladjian</b> , Mihaela C Lazaroiu 10 , Adam Mead , Donal McLornan , Mary F McMullin , Stephen T Oh , Andrew Perkins , Uwe Platzbecker , Christof Scheid , Alessandro Vannucchi , Sung-Soo Yoon , Mark M Kowalski , Ruben A Mesa</p>	<p>MOMENTUM: Momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic</p>	<p>Future oncology</p>	<p><a href="https://doi.org/10.2217/fo-2020-1048">https://doi.org/10.2217/fo-2020-1048</a></p>
<p>Tiziano Barbui, Alessandro Maria Vannucchi, Alberto Alvarez-Larran, Alessandra Iurlo, Arianna Masciulli, Alessandra Carobbio, Arianna Ghirardi, Alberto Ferrari, Giuseppe Rossi, Elena Elli, Marcio Miguel Andrade-Campos, Mercedes Gasior Kabat, <b>Jean-Jacques Kiladjian</b>, Francesca Palandri, Giulia Benevolo, Valentin Garcia-Gutierrez, Maria Laura Fox, Maria Angeles Foncillas, Carmen Montoya Morcillo, Elisa Rumi, Santiago Osorio, Petros Papadopoulos, Massimiliano Bonifacio, Keina Susana Quiroz Cervantes, Miguel Sagues Serrano, Gonzalo Carreno-Tarragona, Marta Anna Sobas, Francesca Lunghi, Andrea Patriarca, Begona Navas Elorza, Anna Angona, Elena Magro Mazo, Steffen Koschmieder, Marco Ruggeri, Beatriz Cuevas, Juan Carlos Hernandez-Boluda, Emma Lopez Abadia, Blanca Xicoy Cirici, Paola Guglielmelli, Marta Garrote, Daniele Cattaneo, Rosa Daffini, Fabrizio Cavalca, Beatriz Bellosillo, <b>Lina Benajiba</b>, Natalia Curto-Garcia, Marta Bellini, Silvia Betti, Valerio De Stefano, Claire Harrison &amp; Alessandro Rambaldi</p>	<p>High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib</p>	<p>leukemia</p>	<p><a href="https://doi.org/10.1038/s41375-020-01107-y">https://doi.org/10.1038/s41375-020-01107-y</a></p>

Hélène Pasquer , Maëlys Tostain , Nina Kaci , Blandine Roux , <b>Lina Benajiba</b>	Descriptive and Functional Genomics in Acute Myeloid Leukemia (AML): Paving the Road for a Cure	Cancers	<a href="https://doi.org/10.3390/cancers13040748">https://doi.org/10.3390/cancers13040748</a>
Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski, Christopher D. Lao, C. Lance Cowey, Dirk Schadendorf, John Wagstaff, MB, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Marcus O. Butler, Andrew Hill, MBCh Ivan M´arquez-Rodas, John B. A. G. Haanen, Massimo Guidoboni, Michele Maio, Patrick Schöffski, Matteo S. Carlino, BMedSc, MBBS, <b>Celeste Lebbe</b> , Grant McArthur, Paolo A. Ascierto, Gregory A. Daniels, Georgina V. Long, Tuba Bas, Corey Ritchings, James Larkin, and F. Stephen Hodi.	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma	Journal of Clinical Oncology	<a href="https://doi.org/10.1200/JCO.21.02229">https://doi.org/10.1200/JCO.21.02229</a>
Lambros Tselikas, Caroline Robert, Stephane Dalle, Nicolas Meyer, <b>Celeste Lebbe</b> , Samy Ammari, François-Xavier Danlos, Severine Roy, Camille Jannin, Siham Farhane, Severine Mourad, Guillaume Escriou, Thibault Raoult, Jean-Yves Scoazec, Matthieu Texier, Nathalie Chaput-Gras, Laurence Zitvogel, Thierry De Baere and Aurélien Marabelle	277 Safety and efficacy of intratumoral ipilimumab with IV nivolumab in metastatic melanoma. The NIVIPIT trial	Journal for ImmunoTherapy of Cancer	<a href="http://dx.doi.org/10.1136/jitc-2021-SITC2021.277">http://dx.doi.org/10.1136/jitc-2021-SITC2021.277</a>
Giovanni Grignani, Piotr Rutkowski, <b>Celeste Lebbe</b> , Natalie Prinzi, Jean-Jacques Grob, Enrica Teresa Tanda, Michele Guida, Melissa Burgess, Jennifer Pulini, Sadhna Shankar, Chuan Tian and Shailender Bhatia	545 A phase 2 study of retifanlimab in patients with advanced or metastatic merkel cell carcinoma (MCC) (POD1UM-201)	Journal for ImmunoTherapy of Cancer	<a href="http://dx.doi.org/10.1136/jitc-2021-SITC2021.545">http://dx.doi.org/10.1136/jitc-2021-SITC2021.545</a>
Paula Codó, Thomas Eigentler, Lucie Heinzerling, Juergen Krauss, Carsten Weishaupt, Sebastian Ochsenreither, <b>Celeste Lebbe</b> , Peter Mohr, Marc Oliva, Honey Oberoi, Patrick Terheyden, José Trigo Pérez, Franz-Georg Bauernfeind, Michael Fluck, Erika Richtig, Ainara Soria, Marina Gonzalez, Fatma Funkner, Peter Wengenmayer, Dominik Vahrenhorst, Tobias Seibel, Gianluca Quintini, Beate Schmitt-Bormann, Birgit Scheel, Martin Falk and Ulrike Gnad-Vogt	473 Immune profiling of patients with advanced solid tumors treated with intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in phase I clinical trial	Journal for ImmunoTherapy of Cancer	<a href="http://dx.doi.org/10.1136/jitc-2021-SITC2021.473">http://dx.doi.org/10.1136/jitc-2021-SITC2021.473</a>
T. Eigentler, L. Heinzerling, J. Krauss, C. Weishaupt, S. Ochsenreither, <b>C. Lebbe</b> , P. Mohr, M. Oliva, H.K. Oberoi, P. Terheyden, J.M. Trigo Perez, C. Robert, F-G. Bauernfeind, M. Fluck, E. Richtig, A. Soria, S-K. Kays, B. Schmitt-Bormann, M. Falk, U.S. Gnad-Vogt	1010P Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008	Annals of Oncology	<a href="https://doi.org/10.1016/j.annonc.2021.08.1394">https://doi.org/10.1016/j.annonc.2021.08.1394</a>

<p>P.A. Ascierto, M. Mandala, P.F. Ferrucci, P. Rutkowski, M. Guidoboni, A.M. Arance Fernandez, V. Ferraresi, E. Maiello, M. Guida, M. Del Vecchio, M.T. Fierro, P. Queirolo, <b>C. Lebbe</b>, H. Helgadottir, I. Melero, G. Palmieri<sup>16</sup>, D. Giannarelli, A.M. Grimaldi, R. Dummer, V. Chiarion Sileni</p>	<p>LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study</p>	<p>Annals of Oncology</p>	<p><a href="http://dx.doi.org/10.1016/j.annonc.2021.08.2118">http://dx.doi.org/10.1016/j.annonc.2021.08.2118</a></p>
<p>Sandra P D'Angelo , <b>Celeste Lebbé</b> , Laurent Mortier , Andrew S Brohl , Nicola Fazio , Jean-Jacques Grob , Natalie Prinzi , Glenn J Hanna , Jessica C Hassel , Felix Kiecker , Sara Georges , Barbara Ellers-Lenz , Parantu Shah , Gülseren Güzel , Paul Nghiem</p>	<p>First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study</p>	<p>Journal for ImmunoTherapy of Cancer</p>	<p><a href="https://doi.org/10.1136/jitc-2021-002646">https://doi.org/10.1136/jitc-2021-002646</a></p>
<p>S P D'Angelo , S Bhatia , A S Brohl , O Hamid , J M Mehnert , P Terheyden , K C Shih , I Brownell , <b>C Lebbé</b> , K D Lewis , G P Linette, M Milella , H Xiong , G Guezel , P T Nghiem</p>	<p>Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up</p>	<p>ESMO Open</p>	<p><a href="https://doi.org/10.1016/j.esmoop.2021.100290">https://doi.org/10.1016/j.esmoop.2021.100290</a></p>
<p><b>Lina Benajiba</b> , Jérôme Lambert , Roberta La Selva , Delphine Cochereau , <b>Barouyr Baroudjian</b> , <b>Jennifer Roux</b> , Jérôme Le Goff , <b>Cécile Pages</b> , Maxime Battistella , <b>Julie Delyon</b> , <b>Céleste Lebbé</b></p>	<p>Systemic Treatment Initiation in Classical and Endemic Kaposi's Sarcoma: Risk Factors and Global Multi-State Modelling in a Monocentric Cohort Study</p>	<p>Cancers</p>	<p><a href="https://doi.org/10.3390/cancers13112519">https://doi.org/10.3390/cancers13112519</a></p>
<p><b>Celeste Lebbe</b>, Nicolas Meyer, Laurent Mortier, Ivan Marquez-Rodas, Caroline Robert, Piotr Rutkowski, Marcus O. Butler, Thomas Eigentler, Alexander M. Menzies, Michael Smylie, Ana Maria Arance, Paolo Antonio Ascierto, Inge Marie Svane, Mazhar Ajaz, Nikhil I. Khushalani, Maurice Lobo, Jesus Zoco, Jacopo Pigozzo</p>	<p>Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.</p>	<p>Journal of Clinical Oncology</p>	<p><a href="https://doi.org/10.1200/JCO.2021.39.15_SUPPL.9516">https://doi.org/10.1200/JCO.2021.39.15_SUPPL.9516</a></p>
<p>Baptiste Louveau , Matthieu Resche-Rigon , Thierry Lesimple , <b>Laetitia Da Meda</b> , Marc Pracht , <b>Barouyr Baroudjian</b> , <b>Julie Delyon</b> , Mona Amini-Adle , Caroline Dutriaux , Coralie Reger de Moura , Aurélie Sadoux , Fanélie Jouenne , <b>Zineb Ghrieb</b> , Paul Vilquin , Didier Bouton , Annick Tibi , Samuel Huguet , Keyvan Rezai , Maxime Battistella , Samia Mourah , <b>Céleste Lebbe</b></p>	<p>Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in BRAF V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism</p>	<p>Clinical Cancer Research</p>	<p><a href="https://doi.org/10.1158/1078-0432.ccr-20-4050">https://doi.org/10.1158/1078-0432.ccr-20-4050</a></p>
<p>Ilene C. Weitz , <b>Régis Peffault de Latour</b> , Jeffrey Szer , Alexander Röth , Britta Höchsmann , Jens Panse , Kensuke Usuki , Morag Griffi n , <b>Jean-Jacques Kiladjian</b> , Carlos M. de Castro , Hisakazu Nishimori , Lisa Tan , Mohammed Al-Adhami , Pascal Deschatelets , Cedric Francois ,Federico Grossi , Antonio Risitano , Peter Hillmen</p>	<p>MDS-134: Efficacy and Safety at 48 Weeks of Pegcetacoplan in Adult Paroxysmal Nocturnal Hemoglobinuria Patients with Suboptimal Response to Prior Eculizumab Treatment</p>	<p>Clinical Lymphoma, Myeloma and Leukemia</p>	<p><a href="https://doi.org/10.1016/S2152-2650(21)01795-X">https://doi.org/10.1016/S2152-2650(21)01795-X</a></p>

<p>Peter Hillmen, M.B., Ch.B., Ph.D., Jeff Szer, M.B., B.S., Ilene Weitz, M.D., Alexander Röth, M.D., Britta Höchsmann, M.D., Jens Panse, M.D., Kensuke Usuki, M.D., Ph.D., Morag Griffin, B.M.Sc., M.B., Ch.B., <b>Jean-Jacques Kiladjian, M.D.</b>, Ph.D., Carlos de Castro, M.D., Hisakazu Nishimori, M.D., Ph.D., Lisa Tan, R.N., Mohamed Hamdani, M.S., Pascal Deschatelets, Ph.D., Cedric Francois, M.D., Ph.D., Federico Grossi, M.D., Ph.D., Temitayo Ajayi, M.D., Antonio Risitano, M.D., Ph.D., and <b>Régis Peffault de la Tour, M.D.</b>,</p>	<p>Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria</p>	<p>The New England Journal of Medicine</p>	<p>DOI: <a href="https://doi.org/10.1056/NEJMoa2029073">10.1056/NEJMoa2029073</a></p>
<p>Laurent Peyrin Biroulet, Ailsa Hart, Peter Bossuyt, Millie Long, <b>Matthieu Allez</b>, Pascal Juillerat, Alessandro Armuzzi, Edward Loftus, Elham Ostad Saffari, Astrid Scalori, Young Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William Sandborn</p>	<p>Etolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial</p>	<p>The Lancet. Gastroenterology &amp; Hepatology</p>	<p><a href="https://doi.org/10.1016/S2468-1253(21)00298-3">https://doi.org/10.1016/S2468-1253(21)00298-3</a></p>
<p>Antonio M Risitano , Alexander Röth , <b>Juliette Soret</b> , Camilla Frieri , <b>Flore Sicre de Fontbrune</b> , Luana Marano , Ferras Alashkar , <b>Lina Benajiba</b> , Serena Marotta , Izabela Rozenberg , Julie Milojevic , Peter End , Prasanna K Nidamarthy , Guido Junge , <b>Régis Peffault de Latour</b></p>	<p>Addition of iptacoplan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial</p>	<p>The Lancet Haematology</p>	<p><a href="https://doi.org/10.1016/S2352-3026(21)00028-4">https://doi.org/10.1016/S2352-3026(21)00028-4</a></p>
<p>David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, <b>Lionel Ades</b>, Aref Al-Kali, Juan M. Alonso-Dominguez, Ana Alfonso-Piérola, Catherine C. Coombs, H. Joachim Deeg, Ian Flinn, James M. Foran, Guillermo Garcia-Manero, Michael B. Maris, Malgorzata McMasters</p>	<p>Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms</p>	<p>Leukemia</p>	<p><a href="https://doi.org/10.1038/s41375-021-01328-9">https://doi.org/10.1038/s41375-021-01328-9</a></p>

<p>           Francois Guilhot, Françoise Rigal-Huguet, Joëlle Guilhot, Agnès-Paule Guerci-Bresler, Frédéric Maloisel, <b>Delphine Rea</b>, Valérie Coiteux, Martine Gardembas, Christian Berthou, Anne Vekhoff, Eric Jourdan, Marc Berger, Loïc Fouillard, Magda Alexis, Laurence Legros, <b>Philippe Rouselot</b>, Alain Delmer, Pascal Lenain, Martine Escoffre Barbe, Emmanuel Gyan, Claude-Eric Bulabois, Viviane Dubruille, Bertrand Joly, Bertrand Pollet, Pascale Cony-Makhoul, Hyacinthe Johnson-Ansah, Melanie Mercier, Denis Caillot, Aude Charbonnier, <b>Jean-Jacques Kiladjian</b>, Jacques Chapiro, Amélie Penot, Véronique Dorvaux, Iona Vaida, Alberto Santagostino, Lydia Roy, Hacene Zerazhi, Eric Deconinck, Herve Maisonneuve, Isabelle Plantier, Delphine Lebon, Yazid Arkam, Nathalie Cambier, Kamel Ghomari, Jean-Michel Miclea, Sylvie Glaisner, Jean-Michel Cayuela, Jean-Claude Chomel, Marc Muller, Ludovic Lhermitte, Marc Delord, Claude Preudhomme, Gabriel Etienne, François-Xavier Mahon &amp; Franck- Emmanuel Nicolini for the France Intergroupe des Leucémies Myéloïdes Chroniques, Fi-LMC         </p>	<p>           Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial         </p>	<p>Leukemia</p>	<p> <a href="https://doi.org/10.1038/s41375-020-01117-w">https://doi.org/10.1038/s41375-020-01117-w</a> </p>
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----------------	--------------------------------------------------------------------------------------------------------------